Drug
Ensifentrine
Ensifentrine: highest development phase Phase 3, developed by Merck, Verona Pharma. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck, Verona Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ensifentrine NCT07874815 | Phase 3 | Pulmonary Disease, Chronic Obstructive |
| Ensifentrine NCT04535986 | Phase 3 | Chronic Obstructive Pulmonary Disease |
| Ensifentrine NCT04542057 | Phase 3 | Chronic Obstructive Pulmonary Disease |
| Ensifentrine 3 mg NCT07132983 | Phase 2 | Chronic Obstructive Pulmonary Disease |
| Ensifentrine NCT05270525 | Phase 2 | COPD |
| Ensifentrine 3 mg NCT07016412 | Phase 2 | Chronic Obstructive Pulmonary Disease |
Latest
No recent events.
Follow Ensifentrine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.